Product portfolio

Donor Screening - Nucleic Acid Testing (NAT)

Bringing safety, reliability and efficiency to donor screening
A single donation of just half a liter of blood can positively affect the lives of multiple patients.

Transplant recipients, accident victims, cancer patients and those undergoing major surgery all rely on safe and readily available supplies of blood and plasma.

As a global leader in the blood and plasma Nucleic Acid Testing (NAT) screening market, Roche partners with some 400 screening centers worldwide to deliver safe, efficient and reliable blood safety solutions.1

These solutions enable continuous productivity and help to reduce the risk of disease transmission and adverse health effects.

Related systems

Product image for cobas® 6800/8800 Systems
Product image for cobas® 6800/8800 Systems
Product image for cobas® S 201

cobas® 6800 System

Transform your testing experience for IVD applications—just 2 simple user interactions per run and up to 8 hours of walk-away time.


cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of high-throughput applications. 


cobas s 201 system

Discover efficiency, reliability and modular automation in the first multi-dye, nucleic acid amplification technology for blood and plasma.



1. Roche Molecular Systems internal customer data base 2015.

Found 0 results in